About Moderna Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.modernatx.com/
Frequently Asked Questions
What is the 52-week range for MRNA?
The 52-week high is $208.9032 and the 52-week low is $22.28.
What is the P/E ratio for MRNA?
The P/E ratio data is currently unavailable.
What is the dividend yield for MRNA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -39.20%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -141.43%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.33.
Analyst Recommendation Trends
Wall Street analyst consensus for MRNA over the last few months:
Latest MRNA News
September's Leaders And Laggards
Technology was the place to be among Septemberâs biggest S&P 500 winners, accounting for 13 of the monthâs 20 best-performing stocks.
Why Is Moderna (MRNA) Bringing Back A Manufacturing Leader As First COO?
Moderna (NasdaqGS:MRNA) appointed Juan Andres as its first Chief Operating Officer as it reshapes its leadership structure. The new COO role focuses on scaling manufacturing for Moderna's personalized cancer vaccine and wider oncology pipeline. Andres returns to Moderna with prior experience overseeing global manufacturing operations at the messenger RNA specialist. The creation of a COO role for Juan Andres only captures part of what is changing inside Moderna right now. Take a look at 1...
Nvidia, Tesla, Seagate, ON Semi, Strategy, HPE, and More Stocks That Explain Today’s Market
Nvidia stock is on pace to close at a record high.
ON Semi, Synaptics, Nike, Strategy, Moderna, and More Stocks That Explain Today’s Market
Nike slumps after the retailer misses analysts’ first-quarter earnings target and issues downbeat fiscal-year guidance.
Warner Bros. Stock Is About to Leave the Nasdaq. Here’s What’s Replacing It.
The entertainment company will exit the Nasdaq after it completes its merger with Paramount Skydance.
Twilio To Join S&P 500 Index
Twilio stock will join the benchmark S&P 500 index before the open on Oct. 6, replacing Warner Bros. Discovery.
Nike, ON Semi, Moderna, and More Stocks That Explain Today’s Market
Nike slumps after the retailer misses analysts’ first-quarter earnings target and issues downbeat full-year guidance.
Nasdaq, S&P 500, Dow Futures Rise Ahead Of Jobs Report: NKE, META, RKLB, MRNA, SLS, TSLA Stocks In Focus
On Stocktwits, retail sentiment toward SPY and QQQ remained ‘bullish’ ahead of jobs data.
Wall Street Breakfast Podcast: No Sprint For Nike Yet
Nikeâs China slump is getting harder to outrun. Moderna is joining the Nasdaq-100. The mortgage industry is bracing for a credit-reporting shake-up.
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on Oct.9.
Micron Says Memory Supply Will Be Much Tighter in 2028. Sandisk's Contracts Limit How Much It Can Gain.
A longer shortage seems like great news for the flash memory specialist. Why did the stock hardly move?
Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Moderna, Inc. (Nasdaq: MRNA) will become a component of the Nasdaq-100 Index® (NDX®) replacing Warner Bros. Discovery, Inc. (Nasdaq: WBD) prior to market open on Friday, October 9, 2026. For additional information, including notifications on changes to any Nasdaq Indexes, please go to https://indexes.nasdaq.com/ About Nasdaq Global Indexes Nasdaq Global Indexes is one of the world's leading index providers, of
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
Moderna (MRNA) closed the most recent trading day at $188.94, moving 1.89% from the previous trading session.
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
Check out the companies making headlines yesterday:
After Moderna's 'Outsized Run,' It May Be Time For This Bearish Move
With potential profit-taking on the horizon, it could mean Moderna's upside is limited in the short-term.
Why Citi Is Sounding the Alarm on Moderna Stock
The cancer pipeline gave Moderna's shares a rocket boost. Citi, however, just checked the stock’s price tag and wasn’t exactly impressed.
Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
Citigroup just told investors to sell Moderna and the stock responded by climbing 3%, raising one pointed question about whether pipeline optimism has fully broken free from Wall Street's valuation warnings.
Moderna Stock Is Trending: What's Going On?
Moderna Inc (NASDAQ:MRNA) shares are trending Thursday as the stock continues working through volatility following a bearish Citi downgrade earlier this week.
Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz
Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight?
Everpure Stock Is September’s Surprise S&P 500 Winner, Surging More Than 40% As Retail Piles In
AI demand, stronger growth targets and index inclusion fuel a standout month for the enterprise-storage company.
If I Could Tell Every New Investor 1 Thing About Building Wealth in the Stock Market, It's This
New investors might be eager to jump in during a bull market.
The Top HealthTech Questions Landing On Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation.
Citi delivers major verdict after Moderna’s remarkable 703% run
Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.
Why Moderna (MRNA) Shares Are Falling Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutral, warning that a 222% rally had pushed its valuation to unsustainable levels.
This Analyst Just Downgraded Moderna Stock. Here's Why.
Citi analyst says Moderna stock could crash as much as 60% from here. Here’s why he issued a bearish note on MRNA shares today.
Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline
Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.
Moderna Stock Slumps as Citi Says It’s Time to Sell After 500% Rally This Year
Moderna’s stock has been flying high lately. That has one group of analysts saying it’s time to sell.
Top S&P500 movers in Wednesday's session
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.
Prediction: Moderna Stock Will Soar 100% by 2030
The company could enter a fresh growth phase.
Sector Update: Healthcare Stocks Softer Wednesday Afternoon
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index easing 0.3% and the S
Moderna, Cerebras, Jabil, HPE, Cal-Maine, Mattel, and More Stocks That Explain Today’s Market
Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.
Stock Market Midday, Sept. 30: Markets Rise on Softer Inflation Data, Investors Await Micron Earnings
Today, Sept. 30, 2026, softer PCE growth is supporting sentiment amid heightened single-stock volatility.
Uncover the latest developments among S&P500 stocks in today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Moderna Shares Reverse Weakness, Rise Over 3% After Key Trading Signal
A key trading signal flashed for Moderna shares at a price of $186.46, after which MRNA rose over 3% to an intraday high.
Moderna and Fair Isaac: The Best and Worst S&P 500 Stocks for the Third Quarter
Moderna stock has rallied since the company unveiled clinical updates to its cancer vaccine in collaboration with Merck in late August.
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.
Wednesday's session: gap up and gap down stock in the S&P500 index
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.
After Moderna's Dizzying Rally, It's Time To Sell, Says Analyst
After nearly quadrupling over the past month, it's time to get out of Moderna stock, a Citi analyst said Wednesday as he downgraded shares.
What's Going On With Moderna Stock on Wednesday?
Moderna stock dips as Juan Andres returns as COO, Jerh Collins retires, and the company expands its vaccine and cancer therapy portfolio.
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat
Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.
Tech leads stocks higher after cooler-than-expected inflation read: AlphaCheck
Here's the market action in the first few minutes of trading.
Target upgraded, Moderna downgraded: Wall Street's top analyst calls
Target upgraded, Moderna downgraded: Wall Street's top analyst calls
Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more
These are the stocks posting the largest moves midday.
Moderna, Concentrix, Boeing, HPE, Robinhood, Cal-Maine, and More Stocks That Explain Today’s Market
Moderna falls after Citi downgrades shares to Sell from Hold, saying its recent rally has gone too far.
Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today
Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron earnings due after the bell Wednesday.
These S&P500 stocks are moving in today's pre-market session
Discover the top S&P500 movers in Wednesday's pre-market session and stay informed about market dynamics.
Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell.
Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.
MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum
Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 melanoma data at ESMO next month.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, BankUnited, Ciena Corporation, CoreWeave, Dow, FormFactor, Lumentum Holdings, Moderna, Target, and More
Rising Treasury yields are rattling markets heading into the final trading day of Q3, and Wall Street analysts are making bold moves on a wide range of stocks from big-box retail to AI infrastructure. Find out who got cut and who got a fresh vote of confidence.
Premarket movers: Micron; Boeing rises, Moderna slides
Investing.com - U.S. stock index futures hovered around the flatline on Wednesday, as investors turned their focus to key inflation data closely watched by the Federal Reserve and upcoming earnings from semiconductor group Micron.
9 Stocks Turn $100,000 to $18.8 Million In 9 Months
September turned out to be a mediocre month for S&P 500 investors. But some stocks wound up having a great month.
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at ModernaCAMBRIDGE, MA / ACCESS Newswire / September 30, 2026 / (NASDAQ:MRNA) today announced the addition of a Chief Operating Officer role to support the increasing scale and diversification of the Company.The new role comes as Moderna prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results and continues to advance a broader onco
This Dow Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded SoundThinking, Moderna, Accelerant, Mobileye and Dow, revising their ratings and price targets.
Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts revised targets and ratings for KMX, ARX, JKHY, MRNA, GO, HNGE, AYTU and MSFT, with mixed upgrades, downgrades and reiterations.
Concentrix Posts Mixed Q3 Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Concentrix plunged 10.6% premarket after weak guidance, despite an earnings beat; several other stocks also traded lower.
Citigroup Downgrades Moderna to Sell, Raises Price Target to $80
Citigroup analyst Geoff Meacham downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $60 to $80.
2 S&P 500 Stocks to Consider Right Now and 1 We Question
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Moderna Sets Another Fresh 52-Week High: What's Happening?
Moderna shares are climbing again Tuesday, touching a new 52-week high of $208.90 on continued momentum from strong clinical trial news.
Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion
Moderna (MRNA) valuation update: stock near bull-case range but central-case implies downside.
Wall Street Breakfast Podcast: Federal Boost For Navitas
A new U.S. government award has Navitas shares surging. After a string of acquisitions, Lilly is hunting for its next big bet. A judge keeps a high-stakes mRNA patent battle alive.
ValuEngine Weekly Commentary: Sector And ETF Performance
U.S. equity markets were mixed this week, with technology and growth-related areas leading, while several defensive and rate-sensitive sectors moved lower. Read more here...
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?
Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.
These S&P500 stocks that are showing activity before the opening bell on Monday.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.
MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data
Laidlaw analyst Yale Jen flagged possible data in other cancers from 2027, while warning that personalized manufacturing costs, capacity and reimbursement could limit commercial success.
Why Did AMD, HPE, MRNA Stocks Surge To 52-Week Highs Last Week?
Investors rewarded companies with strong artificial intelligence demand, enterprise infrastructure, and drug development.
Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success And Middle East Expansion Talks
In recent weeks, Moderna and Merck reported that their Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran autogene plus Keytruda met its primary endpoint in melanoma, with full data presented earlier this month at the European Society for Medical Oncology Congress 2026 and accompanied by growing oncology-focused pipeline visibility. At the same time, Moderna’s talks with Middle East partners about potential investment and manufacturing cooperation highlight how its mRNA...
Moderna (MRNA) Held Investment Talks With The UAE Government
Moderna (NasdaqGS:MRNA) entered high-level investment talks with the UAE government on advanced pharmaceutical manufacturing and R&D collaboration. The discussions focus on expanded research capabilities, potential local production, and broader access to Middle Eastern healthcare markets. Management framed the UAE engagement as part of a wider push to build out Moderna's international footprint beyond existing Western partnerships. The UAE collaboration talks matter, but investors also need...
What Moved Markets This Week
U.S. stocks advanced for the week while Treasury yields surged and petroleum markets remained in focus. Read more about this week's major events on Wall Street.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Moderna (MRNA) concluded the recent trading session at $198.88, signifying a +2.08% move from its prior day's close.
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?
Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.
Stock Market Midday, Sept. 25: AI Momentum Lifts Markets as Akamai Soars on Anthropic Deal
Dow, Nasdaq, and S&P 500 all gain ground despite climbing bond yields, with AI stocks leading the charge, today, Sept. 25, 2026.
AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street
AMD crossed $1 trillion and Meta's Muse rattled subscription stocks. Meanwhile, Treasury yields hit 2007 highs.
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.
Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.
Moderna Stock Reached New 52-Week High: What's Happening?
Moderna Inc. (NASDAQ: MRNA) shares are trading higher Friday, hitting a fresh 52-week high on anticipation of clinical trial data.
Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24.
Key TakeawaysOncology Repricing: Moderna stock jumped 7% on Thursday, September 24, closing at $195 as investors kept betting on intismeran autogene’s Phase 3 melanoma data due at ESMO on October 24. Street Split: The 23 analysts covering Moderna stock are split 4 buys, 1 outperform, 16 holds, 1 underperform, and 1 sell, with a mean target of $120 that sits 39% below Thursday’s close.
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.
Moderna Inc. (MRNA) Holds High-Level Investment Talks With UAE, Soars to 4-Year Peak
Moderna Inc. (NASDAQ:MRNA) saw its share price climb to a new four-year high on Thursday, as investors cheered news that it was exploring investment opportunities in the Middle East. In intra-day trading, the stock climbed to a record high of $195.71 before trimming gains to finish the session just up by 6.98 percent at $194.82 […]
Why is Moderna (MRNA) Stock Trending After Hours?
Moderna shares rose 0.09% after hours Thursday as investors eyed upcoming oncology data at a major European conference.
From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done
The stock was most recently helped by the company CEO’s optimism on its potential outside of COVID vaccines.
Discover which S&P500 stocks are making waves on Thursday.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
Moderna's View of the Global Pharma Industry
Chief executive Stéphane Bancel shares what’s next for Moderna after its report of a breakthrough of its cancer vaccine. He also discusses the state of the FDA and competition from China, AI integration in the drug industry and bioterrorism readiness.
Why Did META, MRNA, OKTA Stocks Surge To 52-Week Highs Today?
Meta Platforms, Moderna and Okta rallied to fresh 52-week highs on Wednesday amid positive company catalysts and improving investor sentiment.
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.
These 2 Stocks Are Bucking The Broader Market Selloff To Hit New Multi-Year Highs — Here’s What’s Driving The Enthusiasm
Moderna and Twilio climbed to multi-year highs on Wednesday, fueled by optimism around Moderna’s broader mRNA pipeline and Twilio’s emerging opportunity from the rapid adoption of AI agents.
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID
Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Office
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Moderna, Inc. (MRNA) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 8:50 AM EDTCompany...
6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewards
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.
Analysts Think 6 S&P 500 Stocks Are Grossly Overvalued
There's a joke on Wall Street that analysts never saw an S&P 500 stock they didn't like. Well, that doesn't seem to be the case now.
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
These ‘Moonshot’ Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.
Moderna (MRNA) Tied To AI Drug Push As Bob Langer Takes New Advisory Role
Moderna (NasdaqGS:MRNA) co-founder Bob Langer has joined the scientific advisory board of Cellular Intelligence, a biotech focused on AI-driven drug development. The appointment aligns with Cellular Intelligence's recent acquisition of a Parkinson's cell therapy program, linking AI discovery with advanced neurology research. Langer's role connects Moderna's mRNA expertise with a growing network of AI medicine collaborations involving Cellular Intelligence and its new Parkinson's therapy...
Moderna (MRNA) Stock Looks Very Expensive As Shares Surge Over 1 Year
Moderna has delivered a very large 1 year share price gain, which puts fresh attention on a basic question. Is the current valuation of the stock supported by the company’s sales profile rather than just recent momentum and headlines? The stock is up a very large amount over the past 12 months, which makes the link between Moderna’s market value and its underlying sales more important for anyone thinking about valuation risk. News around mRNA products, from the mFlusiva flu vaccine launch to...
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success?
The company is looking to prove it can achieve significant success outside the coronavirus market.
Discover which S&P500 stocks are making waves on Tuesday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.
These S&P500 stocks are moving in today's session
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No."
Following last month's super rally, a growing number of analysts are now calling for caution.
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
Moderna has surged over 500% this year while its closest messenger RNA rival sits nearly flat, and a single late-October data presentation at ESMO could either cement the rally or erase it overnight.
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going
Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.
Discover the top S&P500 movers in Tuesday's pre-market session.
Get insights into the top gainers and losers in the S&P500 index of Tuesday's pre-market session.
Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade
Meta's agentic AI assistant Muse lit a fire under tech on Monday, pushing the Nasdaq to a record close and lifting chipmakers by double digits. Cheaper oil, a ten-year yield back below 5% and a friendlier tone between Washington and Beijing did the rest, while Paramount cleared the last big hurdle for its Warner Bros. Discovery takeover.
Top 3 Health Care Stocks That May Keep You Up At Night This Month
Thermo Fisher, Moderna and Agilent show overbought RSI readings above 70, warning momentum-focused investors of potential near-term weakness.
Moderna Stock Jumped 12% Yesterday. An ESMO Presidential Slot Explains Why.
Key TakeawaysPresidential Symposium Slot: Moderna stock jumped 12% to $173 on September 21 after Phase 3 melanoma data for its cancer vaccine, intismeran autogene, earned a spot in ESMO’s Presidential Symposium on October 24. Vaccine Clearance: The FDA cleared updated Spikevax and mNEXSPIKE shots targeting the JN.
September Stagnation Marked By Record-Low Yields, High Duration Risk And High Valuations
Over the first nine months of 2026, we have witnessed a fascinating macro paradox: a surging US stock market decoupling completely from the bond market. Read more here...
Why Did AMD, WBD, MRNA Stocks Surge To 52-Week Highs Today?
Advanced Micro Devices, Warner Bros. Discovery and Moderna stocks surged to annual highs amid a series of positive catalysts.
Moderna (MRNA) Stock Trades Up, Here Is Why
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran autogene, alongside Merck's Keytruda in high-risk melanoma patients continued to drive momentum.
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion
Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business. Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost
Moderna (MRNA) Soars to Fresh High Ahead of Pipeline Updates This Week
Moderna Inc. (NASDAQ:MRNA) rebounded to a new three-year high on Monday, as investors began positioning their portfolios ahead of two upcoming health conferences, one of which will be held on Wednesday, September 23. In intra-day trading, the stock jumped to a new record high of $176.86 before paring gains to hover just above the $174 […]
Monday's session: top gainers and losers in the S&P500 index
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.
Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’
Moderna will showcase detailed melanoma results for Intismeran at ESMO, alongside data and trial updates exploring the personalized therapy in pancreatic and lung cancers.
Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
Moderna’s personalized cancer vaccine, intismeran autogene, will feature at the annual meeting of the European Society for Medical Oncology.
AMD, Intel, Meta, Warner Bros., Moderna, Grail, Strategy, and More Stocks That Explain Today’s Market
Advanced Micro Devices is on pace for its first record high since June 30, and a $1 trillion market cap.
Discover which S&P500 stocks are making waves on Monday.
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Moderna (NASDAQ:MRNA) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy, was selected for a Presidential Symposium slot at the European Society for Medical Oncology congress in Madrid. The stock is at $167.90, up 9% in Monday morning […]
AZN vs. MRK: Comparing Keytruda, Pipelines and Growth Strategies
AZN and MRK bring distinct oncology strengths, growth plans, pipeline opportunities and patent-related challenges to the table.
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
The presentation details are as follows:Presidential Symposium: * LBA1- INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Session Type/Title: Presidential Symposium Date & Time: Saturday, October 24, 4:30 PM CEST / 10:30 AM EDT Presenter: Georgina V. Long (Sydney, Australia, NSW)Poster Presentations: * Abstract 3151P: Adj
Moderna Stock Is Soaring: What's Going On?
Moderna shares are surging Monday. The company announced three intismeran autogene abstracts were accepted for presentation at ESMO Congress.
Moderna To Present Three Abstracts On Intismeran Autogene At European Society For Medical Oncology Congress 2026
Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for
Critical Metals, Priority Technology, Meta Platforms And Other Big Stocks Moving Higher On Monday
U.S. stocks rose Monday, with Nasdaq up 1%. Critical Metals jumped 38% on Greenland deal news as tech and other shares broadly gained.
Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug
CI is pairing top AI and biotech minds on its board (plus an advisory role for OpenAI's Fidji Simo) as it tests models on a Novo Nordisk drug.
Dow Jones Futures Rise; Can The Market Take Flight? Robinhood, Sandisk, AMD, Moderna Surge Into Buy Areas
The stock market showed choppy, mixed weekly action. But Robinhood, Sandisk, AMD and Moderna rallied into buy areas.
3 Bullish Setups for the Week Ahead
As the bulls reassert their power, leading stocks like SanDisk, Coinbase, and Moderna are setting up in constructive base structures.
Dow Jones Futures Due: Can The Market Take Flight? Robinhood, Sandisk, AMD, Moderna Surge Into Buy Areas
The stock market showed choppy, mixed weekly action. But Robinhood, Sandisk, AMD and Moderna rallied into buy areas.
Dow Jones Futures: Can The Market Rally Take Flight? Robinhood, Sandisk, AMD, Moderna Surge Into Buy Areas
The stock market showed choppy, mixed weekly action. But Robinhood, Sandisk, AMD and Moderna rallied into buy areas.
Dow Jones Futures: Will The Market Rally Take Flight? Robinhood, Sandisk, AMD, Moderna Surge Into Buy Areas
The stock market showed choppy, mixed weekly action. But Robinhood, Sandisk, AMD and Moderna rallied into buy areas.
The Next Big Theme: September 2026
Data center construction spending increased nearly 60% YoY in July 2026 to surpass a $75 billion annualized pace as AI translates into a major U.S. construction cycle. Read more here.
Benzinga Bulls and Bears: Generac, Salesforce, Netflix
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Moderna (MRNA) Dropped, So What Is Behind The Latest Attention?
Moderna (MRNA) has been back in the spotlight after its appearance at the Morgan Stanley Global Healthcare Conference, where management highlighted progress across its vaccine portfolio and ongoing Phase 3 work on personalized cancer candidate intismeran. Recent trading has been volatile for Moderna, with a 1-day share price return that declined 2.55% after the latest close at US$154.04. However, a 7-day share price return of 6.99% and a 90-day gain of 140.84% indicate upward momentum that...
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said
Dow Jones Futures: Nasdaq, S&P 500 Hold; Robinhood, Sandisk, AMD, Moderna Surge Into Buy Areas
The stock market showed choppy, mixed weekly action. But Robinhood, Sandisk, AMD and Moderna rallied into buy areas.
Dow Jones Futures: Market Still Choppy; Robinhood, Sandisk, AMD, Moderna Surge Into Buy Areas
The stock market showed choppy, mixed weekly action. But Robinhood, Sandisk, AMD and Moderna rallied into buy areas.
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases to target.
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
One stock is up 540%, and it's not alone
Some of the market's strongest large-cap performers are clustering around chips, memory and AI infrastructure.
Dow Jones Futures: After S&P 500, Nasdaq Rebound, What's Next? Moderna, AMD, SpaceX Flash Buy Signals.
The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.
A Bear Market Is Coming -- We Just Don't Know When. Here's What History Says You Must Do to Get Through It Relatively Unscathed.
With a plan in place, it's possible to make the most of a bear market.
BUZZ Investing: Rising Oil Prices And Treasury Yields Pressure Equities
The S&P 500 declined 2.5% and Nasdaq Composite 2.6% between selection dates (August 13 â September 10, 2026), while the BUZZ Index held up better with a 0.8% decline. Read more here.
Zacks Investment Ideas feature highlights: NVIDIA, Advanced Micro Devices, Tempus, Moderna, Super Micro Computer and Aya Gold & Silver
NVIDIA, Advanced Micro Devices, Tempus, Moderna, Super Micro Computer and Aya Gold & Silver have been highlighted in this Investment Ideas article.
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.
Dow Jones Futures: S&P 500, Nasdaq Rebound Above Key Level; Moderna, AMD, SpaceX Flash Buy Signals
The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.
Dow Jones Futures Fall After S&P 500, Nasdaq Rebound Above Key Level; Moderna, AMD, SpaceX Flash Buy Signals
The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.
Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04
Why Are Moderna (MRNA) Shares Soaring Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 7.1% in the afternoon session after the company presented at the Morgan Stanley Global Healthcare Conference and generated positive sentiment around its vaccine pipeline.
Will 2026 Doom and Gloom Lead to Opportunity?
While macroeconomic headwinds, geopolitical energy shocks, and relentless media fear-mongering might suggest a market correction is overdue, the resilience of stock price action tells a different story.
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Which S&P500 stocks are moving on Thursday?
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Moderna: Another Day, Another Big Stock Move. Is the Cancer Vaccine Rally Back On?
Moderna President Stephen Hoge says the company remains on track for its longtime goal of reaching cash breakeven by 2028.
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.
Nasdaq 100 Rallies as Oil Slides, Yields Retreat: Stock Market Today
Wall Street snapped a two-day losing streak Thursday as oil retreated from its geopolitical spike and the 10-year Treasury yield slipped back below 5%. Chipmakers led the rebound, with Intel, AMD and Micron all posting outsized gains, while gold climbed 2.5% to $4,369 an ounce. The bounce came one day after the Federal Reserve delivered its first interest rate hike since 2023 and signaled at least one more this year.
Moderna Stock Is Surging: What's Going On?
Moderna Inc. (NASDAQ: MRNA) shares are popping Thursday, extending a month-long rally that began with a Phase 3 cancer vaccine breakthrough.
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
Moderna stock has more than doubled after its cancer-vaccine breakthrough. Now investors face the harder question: Can it become an oncology powerhouse?
Thursday's pre-market session: top gainers and losers in the S&P500 index
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.
This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%
Merck is beating the market year-to-date after a jump on positive Phase 3 data, while paying an annualized dividend of about $3.40 for a yield above 2.3%.
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
Cancer progress, a broader pipeline and vaccine expansion help MRNA rebuild beyond COVID-19, but can oncology drive its next growth phase?
AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline
AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s established SKYRIZI and RINVOQ franchises. Speaking at a Morgan Stanley event, Chairman and Chief E
Unpopular Stocks Walking a Fine Line
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
HQL: The Rally That Makes Growth Harder (Rating Downgrade)
HQL downgraded to Hold after big rally; 12.5% yield, NAV discount and payout risks weigh on upside.
Finding Value Opportunities Among Highly Rated Stocks
U.S. equity markets moved lower this week, with broad weakness across most major ETFs and sector benchmarks.
Moderna (MRNA) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, Moderna (MRNA) stood at $146.69, denoting a +1.89% move from the preceding trading day.
Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets
Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing convenience, according to Ilya Yuffa, the company’s executive vice president and president of Lilly USA and G
Moderna's COVID Vaccine Was a Historic Success. Could Its Cancer Vaccine Be Even Bigger?
The biotech is entering a new era.
3 Cash-Burning Stocks We Approach with Caution
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort to use T-cell priming in multiple tumor types. Speaking at a Morgan Stanley ev
Wall Street Lunch: Tesla's Roadster Could Be Ready To Take Flight
Tesla (TSLA) has an Oct. 1 event scheduled that is expected to be a public unveiling or major update for the long-delayed second-generation Roadster model.
Moderna, Inc. (MRNA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Moderna, Inc. (MRNA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDTCompany ParticipantsStephen Hoge -...
The Melanoma Win Is Real, The Price Isn't - Moderna And MRNY Both Sell
Moderna (MRNA) and MRNY are rated Sell on stretched valuation after melanoma Phase 3 news.
Dow Jones Futures: Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
Dow Jones Futures Fall, Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
Dow Jones Futures: Will Anthropic-Led Call For Slowdown Hit AI Stocks? Fed Meeting Ahead
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
Dow Jones Futures: AI Stocks In Focus As Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
Dow Jones Futures: Fed Meeting Ahead; Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI Slowdown
Anthropic's Dario Amodei, OpenAI's and SpaceX's Elon Musk say they want an AI slowdown. Will they? The Fed looms as well.
Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys
Despite Friday's bounce, stocks are struggling amid surging oil prices and yields, though Apple, Moderna are buys. The Fed meeting looms.
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
Dow Jones Futures: $100 Oil, Surging Yields Pressure Stocks With Fed Rate Hike Seen. Apple Leads New Buys.
Dow Jones futures: Despite Friday's bounce, the stock market had a tough week amid $100 oil prices and surging Treasury yields. Apple, Moderna are buys.
How Cathie Wood's Fund Gave Us A Back Door To Moderna's Breakthrough
Moderna had too much volatility as a swing trade. But ARK Genomics Revolution ETF allowed us to manage risk better.
Top S&P500 movers in Friday's session
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Stay informed with the top movers within the S&P500 index on Friday.
Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat
Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains why.
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Frequency Electronics, ACV Auctions, HP And Other Big Stocks Moving Higher On Friday
U.S. stocks rose; Frequency Electronics surged 30.7% after beating Q1 estimates, while ACV Auctions jumped 44.3% on Copart’s acquisition deal.
Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions
A congresswoman recently bought stocks connected to Warren Buffett and Elon Musk.
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.
mRNA cancer vaccines’ biggest barriers to market
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
AI And Robotics In 2026: 16 Recent Developments For Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating.
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference
AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit i
Influenza A Market Insight, Epidemiology, and Market Forecast - 2036 Now Available — See Why a 70% Vaccine Failure Rate Is Fueling the Race for Next-Gen Flu Therapies
178-Page Report Tracks Merck's Cidara Buyout and CD388's Phase 3 Launch as Roche, Moderna, and GSK Compete Beyond the Vaccine Status QuoDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Influenza a Infections - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. A new "Influenza A - Market Insights, Epidemiology, and Market Forecast - 2036" report provides a comprehensive analysis of the Influenza A market across the United States, EU4 cou
ValuEngine Weekly Commentary: Advancing Nuclear Energy And Evaluating Its Current Place Within Dynamic Asset Strategies
U.S. equity markets were mostly mixed this week, with modest gains in the major benchmarks masking weakness across several sectors.
AI, Cancer Vaccines, and Next-Gen Medicine
Could cancer vaccines and AI drive the next wave of healthcare innovation?
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.
Cancer Vaccines & Data Center Drama
Data centers face drama as public pushback against the AI build-out is at a high.
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.
Behind the Most Exciting Stock Pop in Years
Moderna's stock is up over 100%.
The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI
Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.
8 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans
How Is Moderna's Stock Performance Compared to Other Healthcare Stocks
Moderna has outpaced the healthcare sector, yet analysts remain skeptical about the stock’s outlook.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)
Moderna shares have soared, sunk, and soared again. You might want to consider them.
Summer Flings And Heartbreaks
Since the close on the Thursday before Memorial Day, the S&P 500 has rallied 3.7%. Read more here.
What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?
Moderna (NasdaqGS:MRNA) has started a Phase 3 trial of its mRNA based bird flu vaccine, moving the program into late stage testing. The trial is supported by a major international partnership focused on pandemic preparedness. Moderna has tied the program to commitments for equitable global access, including reserved manufacturing capacity for low and middle income countries. This push into mRNA vaccines for emerging infectious diseases points to a wider theme in healthcare that is worth...
Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?
Moderna (MRNA) drew fresh attention after completing a US$2.6b zero coupon convertible notes offering due 2032 and separately announcing an additional US$2b 2032 convertible notes issue, both placed under Rule 144A. Moderna's recent completion of zero coupon notes and the additional 2032 convertible announcement come after a surge in momentum, with the share price delivering a 30 day return of 158.73% and a year to date share price return of 371.65%, while the 1 year total shareholder return...
Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?
The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.
Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run
Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current price already reflects much of the good news around the mRNA pipeline. The share price return over the past 12 months is above 500%, which sets a high bar for what future progress on products and earnings needs to justify. Recent approvals for updated COVID vaccines and the first mRNA flu shot,...
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says
GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...
3 Inflated Stocks with Open Questions
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Why Moderna (MRNA) Stock Is Down Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation concerns. Baker raised Moderna's price target to $81 from $40, representing a 46% downside from the previous day’s close of $150.81, CNBC reported.
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
Both have attracted considerable attention from Wall Street recently.
Thursday's session: top gainers and losers in the S&P500 index
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.
Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 45% Stock Drop
Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
Bamco, the advisory arm of Ron Baron’s Baron Capital Group, opened a new position in Moderna (NASDAQ:MRNA) during the second quarter of 2026. The fund bought about 2 million shares of the firm in the June quarter. The timing worked out. In August, Moderna shares nearly tripled on a positive Phase 3 report. Bamco also […]
Why Moderna's Cancer Vaccine Matters To Investors
As legacy pharmaceutical models face structural challenges, targeting the underlying technology enablers of next-generation care offers a compelling approach for healthcare investors.
Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls
Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.
This Sonoco Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Analysts downgraded Ultragenyx, Moderna and Sonoco; targets fell for RARE and SON but rose for MRNA.
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts revised price targets for Ultragenyx, UiPath, Netskope, Snowflake, Magnite, Broadcom, CrowdStrike and Moderna; ratings largely maintained.
Rothschild & Co Downgrades Moderna to Sell, Raises Price Target to $81
Rothschild & Co analyst Simon Baker downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $40 to $81.
Moderna: Massive Asymmetry About What The mRNA Is!
Moderna's upside hinges on Intismeranâs ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock is a strong buy.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Hoge Stephen | -76,452 | - | - |
| 2026-09-15 | Hoge Stephen | -40,281 | $146.07 | $5,883,846 |
| 2026-09-15 | Hoge Stephen | +76,452 | $12.21 | $933,479 |
| 2026-09-14 | Hoge Stephen | -76,453 | - | - |
| 2026-09-14 | Hoge Stephen | -40,294 | $144.13 | $5,807,574 |
| 2026-09-14 | Hoge Stephen | +76,453 | $12.21 | $933,491 |
| 2026-09-10 | Mock James M | -19,836 | - | - |
| 2026-09-10 | Mock James M | -15,000 | $134.49 | $2,017,350 |
| 2026-09-10 | Mock James M | -19,836 | $134.49 | $2,667,744 |
| 2026-09-10 | Mock James M | +19,836 | $30.96 | $614,123 |
| 2026-09-04 | Mock James M | -11,797 | - | - |
| 2026-09-04 | Mock James M | -5,704 | $148.87 | $849,154 |
| 2026-09-04 | Mock James M | +11,797 | - | - |
| 2026-09-04 | Klinger Shannon Thyme | -11,797 | - | - |
| 2026-09-04 | Klinger Shannon Thyme | -5,704 | $148.87 | $849,154 |
| 2026-09-04 | Klinger Shannon Thyme | +11,797 | - | - |
| 2026-09-01 | Klinger Shannon Thyme | -2,166 | - | - |
| 2026-09-01 | Klinger Shannon Thyme | -3,471 | - | - |
| 2026-09-01 | Klinger Shannon Thyme | -1,048 | $140.34 | $147,076 |
| 2026-09-01 | Klinger Shannon Thyme | +2,166 | - | - |
| 2026-09-01 | Klinger Shannon Thyme | -3,471 | $139.95 | $485,766 |
| 2026-09-01 | Klinger Shannon Thyme | +3,471 | $30.96 | $107,462 |
| 2026-09-01 | Mock James M | -2,475 | - | - |
| 2026-09-01 | Mock James M | -1,197 | $140.34 | $167,987 |
| 2026-09-01 | Mock James M | +2,475 | - | - |
| 2026-09-01 | Hoge Stephen | -9,283 | - | - |
| 2026-09-01 | Hoge Stephen | -4,489 | $140.34 | $629,986 |
| 2026-09-01 | Hoge Stephen | +9,283 | - | - |
| 2026-08-28 | Hoge Stephen | -611 | - | - |
| 2026-08-28 | Hoge Stephen | -296 | $142.77 | $42,260 |
| 2026-08-28 | Hoge Stephen | +611 | - | - |
| 2026-08-28 | Klinger Shannon Thyme | -329 | - | - |
| 2026-08-28 | Klinger Shannon Thyme | -160 | $142.77 | $22,843 |
| 2026-08-28 | Klinger Shannon Thyme | +329 | - | - |
| 2026-08-28 | Mock James M | -329 | - | - |
| 2026-08-28 | Mock James M | -160 | $142.77 | $22,843 |
| 2026-08-28 | Mock James M | +329 | - | - |
| 2026-08-27 | Hoge Stephen | -1,437 | - | - |
| 2026-08-27 | Hoge Stephen | -695 | $149.66 | $104,014 |
| 2026-08-27 | Hoge Stephen | +1,437 | - | - |
| 2026-08-27 | Klinger Shannon Thyme | -774 | - | - |
| 2026-08-27 | Klinger Shannon Thyme | -375 | $149.66 | $56,123 |
| 2026-08-27 | Klinger Shannon Thyme | +774 | - | - |
| 2026-08-27 | Mock James M | -774 | - | - |
| 2026-08-27 | Mock James M | -375 | $149.66 | $56,123 |
| 2026-08-27 | Mock James M | +774 | - | - |
| 2026-08-06 | Bancel Stephane | -64,928 | - | - |
| 2026-08-06 | Bancel Stephane | -187,541 | - | - |
| 2026-08-06 | Bancel Stephane | +252,469 | $19.15 | $4,834,781 |
| 2026-08-05 | Bancel Stephane | -128,393 | - | - |
| 2026-08-05 | Bancel Stephane | -370,853 | - | - |
| 2026-08-05 | Bancel Stephane | -187,044 | $58.79 | $10,996,317 |
| 2026-08-05 | Bancel Stephane | -39,891 | $58.12 | $2,318,465 |
| 2026-08-05 | Bancel Stephane | -124,838 | $56.96 | $7,110,772 |
| 2026-08-05 | Bancel Stephane | -147,473 | $56.21 | $8,289,457 |
| 2026-08-05 | Bancel Stephane | +499,246 | $19.15 | $9,560,561 |
| 2026-07-15 | Hoge Stephen | -16,110 | - | - |
| 2026-07-15 | Hoge Stephen | -37,226 | - | - |
| 2026-07-15 | Hoge Stephen | -53,336 | $67.6 | $3,605,514 |
| 2026-07-15 | Hoge Stephen | +16,110 | $19.15 | $308,507 |
| 2026-07-15 | Hoge Stephen | +37,226 | $19.15 | $712,878 |
| 2026-07-08 | McDonnell Michael R. | +5,733 | - | - |
| 2026-07-08 | McDonnell Michael R. | +1,618 | - | - |
| 2026-07-08 | McDonnell Michael R. | +7,415 | - | - |
| 2026-07-05 | Banque Soria Ester | +38,364 | - | - |
| 2026-07-05 | Banque Soria Ester | +18,658 | - | - |
| 2026-07-02 | Mock James M | -1,452 | - | - |
| 2026-07-02 | Mock James M | -703 | $72.5 | $50,968 |
| 2026-07-02 | Mock James M | +1,452 | - | - |
| 2026-06-05 | Klinger Shannon Thyme | -11,798 | - | - |
| 2026-06-05 | Klinger Shannon Thyme | -5,705 | $51.59 | $294,321 |
| 2026-06-05 | Klinger Shannon Thyme | +11,798 | - | - |
| 2026-06-05 | Mock James M | -11,798 | - | - |
| 2026-06-05 | Mock James M | -5,705 | $51.59 | $294,321 |
| 2026-06-05 | Mock James M | +11,798 | - | - |
| 2026-06-04 | Klinger Shannon Thyme | -3,471 | - | - |
| 2026-06-04 | Klinger Shannon Thyme | -3,471 | $50 | $173,550 |
| 2026-06-04 | Klinger Shannon Thyme | +3,471 | $30.96 | $107,462 |
| 2026-06-01 | Mock James M | -2,475 | - | - |
| 2026-06-01 | Mock James M | -1,197 | $47.19 | $56,486 |
| 2026-06-01 | Mock James M | +2,475 | - | - |
| 2026-06-01 | Klinger Shannon Thyme | -2,165 | - | - |
| 2026-06-01 | Klinger Shannon Thyme | -1,047 | $47.19 | $49,408 |
| 2026-06-01 | Klinger Shannon Thyme | +2,165 | - | - |
| 2026-06-01 | Hoge Stephen | -9,282 | - | - |
| 2026-06-01 | Hoge Stephen | -4,488 | $47.19 | $211,789 |
| 2026-06-01 | Hoge Stephen | +9,282 | - | - |
| 2026-05-28 | Mock James M | -328 | - | - |
| 2026-05-28 | Mock James M | -159 | $47.61 | $7,570 |
| 2026-05-28 | Mock James M | +328 | - | - |
| 2026-05-28 | Klinger Shannon Thyme | -328 | - | - |
| 2026-05-28 | Klinger Shannon Thyme | -159 | $47.61 | $7,570 |
| 2026-05-28 | Klinger Shannon Thyme | +328 | - | - |
| 2026-05-28 | Hoge Stephen | -610 | - | - |
| 2026-05-28 | Hoge Stephen | -295 | $47.61 | $14,045 |
| 2026-05-28 | Hoge Stephen | +610 | - | - |
| 2026-05-27 | Mock James M | -773 | - | - |
| 2026-05-27 | Mock James M | -374 | $47.03 | $17,589 |
| 2026-05-27 | Mock James M | +773 | - | - |
| 2026-05-27 | Klinger Shannon Thyme | -773 | - | - |
| 2026-05-27 | Klinger Shannon Thyme | -374 | $47.03 | $17,589 |
| 2026-05-27 | Klinger Shannon Thyme | +773 | - | - |
| 2026-05-27 | Hoge Stephen | -1,437 | - | - |
| 2026-05-27 | Hoge Stephen | -695 | $47.03 | $32,686 |
| 2026-05-27 | Hoge Stephen | +1,437 | - | - |
| 2026-05-21 | AFEYAN NOUBAR | -9,263 | - | - |
| 2026-05-21 | AFEYAN NOUBAR | -9,263 | $46.84 | $433,879 |
| 2026-05-21 | AFEYAN NOUBAR | +9,263 | $19.15 | $177,386 |
| 2026-05-15 | Hoge Stephen | -16,110 | - | - |
| 2026-05-15 | Hoge Stephen | -37,226 | - | - |
| 2026-05-15 | Hoge Stephen | -53,336 | $48.4 | $2,581,462 |
| 2026-05-15 | Hoge Stephen | +16,110 | $19.15 | $308,507 |
| 2026-05-15 | Hoge Stephen | +37,226 | $19.15 | $712,878 |
| 2026-05-06 | Nader Francois | +4,185 | - | - |
| 2026-05-06 | Nader Francois | +6,454 | - | - |
| 2026-05-06 | Tallett Elizabeth E | +8,371 | - | - |
| 2026-05-06 | Hussain Abbas | +8,371 | - | - |
| 2026-05-06 | Horning Sandra | +2,092 | - | - |
| 2026-05-06 | Horning Sandra | +9,681 | - | - |
| 2026-05-06 | NABEL ELIZABETH G | +8,371 | - | - |
| 2026-05-06 | Rubenstein David M. | +2,092 | - | - |
| 2026-05-06 | Rubenstein David M. | +9,681 | - | - |
| 2026-05-06 | AFEYAN NOUBAR | +12,908 | - | - |
| 2026-05-01 | Hussain Abbas | -5,682 | $46.63 | $264,952 |
| 2026-04-30 | Hussain Abbas | -16,233 | - | - |
| 2026-04-30 | Hussain Abbas | +16,233 | - | - |
| 2026-04-30 | Horning Sandra | -16,233 | - | - |
| 2026-04-30 | Horning Sandra | +16,233 | - | - |
| 2026-04-30 | NABEL ELIZABETH G | -16,233 | - | - |
| 2026-04-30 | NABEL ELIZABETH G | +16,233 | - | - |
| 2026-04-30 | Rubenstein David M. | -8,116 | - | - |
| 2026-04-30 | Rubenstein David M. | +8,116 | - | - |
| 2026-04-30 | Nader Francois | -12,174 | - | - |
| 2026-04-30 | Nader Francois | +12,174 | - | - |
| 2026-04-30 | Tallett Elizabeth E | -4,058 | - | - |
| 2026-04-30 | Tallett Elizabeth E | +4,058 | - | - |
| 2026-04-02 | Mock James M | -1,453 | - | - |
| 2026-04-02 | Mock James M | -703 | $50.03 | $35,171 |
| 2026-04-02 | Mock James M | +1,453 | - | - |
| 2026-03-05 | Klinger Shannon Thyme | -11,797 | - | - |
| 2026-03-05 | Klinger Shannon Thyme | -5,704 | $57.8 | $329,691 |
| 2026-03-05 | Klinger Shannon Thyme | +11,797 | - | - |
| 2026-03-05 | Mock James M | -11,797 | - | - |
| 2026-03-05 | Mock James M | -5,704 | $57.8 | $329,691 |
| 2026-03-05 | Mock James M | +11,797 | - | - |
| 2026-03-02 | Klinger Shannon Thyme | -13,885 | - | - |
| 2026-03-02 | Klinger Shannon Thyme | -13,885 | $52.29 | $726,047 |
| 2026-03-02 | Klinger Shannon Thyme | +13,885 | $30.96 | $429,880 |
| 2026-03-01 | Klinger Shannon Thyme | +38,553 | - | - |
| 2026-03-01 | Klinger Shannon Thyme | +29,275 | - | - |
| 2026-03-01 | Hoge Stephen | +165,230 | - | - |
| 2026-03-01 | Hoge Stephen | +125,466 | - | - |
| 2026-03-01 | Mock James M | +49,569 | - | - |
| 2026-03-01 | Mock James M | +37,639 | - | - |
| 2026-03-01 | Bancel Stephane | +250,932 | - | - |
| 2026-02-27 | Klinger Shannon Thyme | -8,663 | - | - |
| 2026-02-27 | Klinger Shannon Thyme | -774 | - | - |
| 2026-02-27 | Klinger Shannon Thyme | -329 | - | - |
| 2026-02-27 | Klinger Shannon Thyme | -233 | - | - |
| 2026-02-27 | Klinger Shannon Thyme | -4,189 | $51.71 | $216,613 |
| 2026-02-27 | Klinger Shannon Thyme | +8,663 | - | - |
| 2026-02-27 | Klinger Shannon Thyme | -375 | $51.71 | $19,391 |
| 2026-02-27 | Klinger Shannon Thyme | +774 | - | - |
| 2026-02-27 | Klinger Shannon Thyme | -160 | $51.71 | $8,274 |
| 2026-02-27 | Klinger Shannon Thyme | +329 | - | - |
| 2026-02-27 | Klinger Shannon Thyme | -113 | $51.71 | $5,843 |
| 2026-02-27 | Klinger Shannon Thyme | +233 | - | - |
| 2026-02-27 | Hoge Stephen | -37,131 | - | - |
| 2026-02-27 | Hoge Stephen | -1,436 | - | - |
| 2026-02-27 | Hoge Stephen | -611 | - | - |
| 2026-02-27 | Hoge Stephen | -652 | - | - |
| 2026-02-27 | Hoge Stephen | -17,953 | $51.71 | $928,350 |
| 2026-02-27 | Hoge Stephen | +37,131 | - | - |
| 2026-02-27 | Hoge Stephen | -695 | $51.71 | $35,938 |
| 2026-02-27 | Hoge Stephen | +1,436 | - | - |
| 2026-02-27 | Hoge Stephen | -296 | $51.71 | $15,306 |
| 2026-02-27 | Hoge Stephen | +611 | - | - |
| 2026-02-27 | Hoge Stephen | -316 | $51.71 | $16,340 |
| 2026-02-27 | Hoge Stephen | +652 | - | - |
| 2026-02-27 | Mock James M | -9,901 | - | - |
| 2026-02-27 | Mock James M | -774 | - | - |
| 2026-02-27 | Mock James M | -329 | - | - |
| 2026-02-27 | Mock James M | -4,788 | $51.71 | $247,587 |
| 2026-02-27 | Mock James M | +9,901 | - | - |
| 2026-02-27 | Mock James M | -375 | $51.71 | $19,391 |
| 2026-02-27 | Mock James M | +774 | - | - |
| 2026-02-27 | Mock James M | -160 | $51.71 | $8,274 |
| 2026-02-27 | Mock James M | +329 | - | - |
| 2026-02-23 | Hoge Stephen | -48,330 | - | - |
| 2026-02-23 | Hoge Stephen | -111,679 | - | - |
| 2026-02-23 | Hoge Stephen | -160,009 | $48.84 | $7,814,840 |
| 2026-02-23 | Hoge Stephen | +48,330 | $19.15 | $925,519 |
| 2026-02-23 | Hoge Stephen | +111,679 | $19.15 | $2,138,653 |
| 2026-02-11 | Mock James M | -1,278 | $41.99 | $53,663 |
| 2026-02-11 | Mock James M | +2,630 | - | - |
| 2026-02-11 | Klinger Shannon Thyme | -1,334 | $41.99 | $56,015 |
| 2026-02-11 | Klinger Shannon Thyme | +2,630 | - | - |
| 2026-02-11 | Hoge Stephen | -2,362 | $41.99 | $99,180 |
| 2026-02-11 | Hoge Stephen | +4,884 | - | - |
| 2026-02-11 | Bancel Stephane | -5,450 | $41.99 | $228,846 |
| 2026-02-11 | Bancel Stephane | +11,271 | - | - |
| 2026-01-05 | Mock James M | -1,452 | - | - |
| 2026-01-05 | Mock James M | -780 | $30.86 | $24,071 |
| 2026-01-05 | Mock James M | +1,452 | - | - |
| 2025-12-11 | Bancel Stephane | -688,073 | - | - |
| 2025-12-11 | Bancel Stephane | +688,073 | $10.9 | $7,499,996 |
| 2025-12-11 | AFEYAN NOUBAR | -23,853 | - | - |
| 2025-12-11 | AFEYAN NOUBAR | -23,853 | $29.485 | $703,306 |
| 2025-12-11 | AFEYAN NOUBAR | +23,853 | $10.9 | $259,998 |
| 2025-12-09 | Hussain Abbas | -504 | $27.6 | $13,910 |
| 2025-12-05 | Mock James M | -47,190 | - | - |
| 2025-12-05 | Mock James M | -22,817 | $25.49 | $581,605 |
| 2025-12-05 | Mock James M | +47,190 | - | - |
| 2025-12-05 | Klinger Shannon Thyme | -47,190 | - | - |
| 2025-12-05 | Klinger Shannon Thyme | -22,817 | $25.49 | $581,605 |
| 2025-12-05 | Klinger Shannon Thyme | +47,190 | - | - |
| 2025-12-01 | Klinger Shannon Thyme | -233 | - | - |
| 2025-12-01 | Klinger Shannon Thyme | -113 | $25.98 | $2,936 |
| 2025-12-01 | Klinger Shannon Thyme | +233 | - | - |
| 2025-12-01 | Hoge Stephen | -652 | - | - |
| 2025-12-01 | Hoge Stephen | -316 | $25.98 | $8,210 |
| 2025-12-01 | Hoge Stephen | +652 | - | - |
| 2025-11-28 | Mock James M | -329 | - | - |
| 2025-11-28 | Mock James M | -160 | $25.01 | $4,002 |
| 2025-11-28 | Mock James M | +329 | - | - |
| 2025-11-28 | Klinger Shannon Thyme | -329 | - | - |
| 2025-11-28 | Klinger Shannon Thyme | -160 | $25.01 | $4,002 |
| 2025-11-28 | Klinger Shannon Thyme | +329 | - | - |
| 2025-11-28 | Hoge Stephen | -610 | - | - |
| 2025-11-28 | Hoge Stephen | -295 | $25.01 | $7,378 |
| 2025-11-28 | Hoge Stephen | +610 | - | - |
| 2025-11-26 | Mock James M | -773 | - | - |
| 2025-11-26 | Mock James M | -374 | $24.75 | $9,257 |
| 2025-11-26 | Mock James M | +773 | - | - |
| 2025-11-26 | Klinger Shannon Thyme | -773 | - | - |
| 2025-11-26 | Klinger Shannon Thyme | -374 | $24.75 | $9,257 |
| 2025-11-26 | Klinger Shannon Thyme | +773 | - | - |
| 2025-11-26 | Hoge Stephen | -1,437 | - | - |
| 2025-11-26 | Hoge Stephen | -695 | $24.75 | $17,201 |
| 2025-11-26 | Hoge Stephen | +1,437 | - | - |
| 2025-10-03 | Mock James M | -1,453 | - | - |
| 2025-10-03 | Mock James M | -703 | $28.37 | $19,944 |
| 2025-10-03 | Mock James M | +1,453 | - | - |